BioMarin Appoints Richard Ranieri as Senior Vice President, Human Resources
and Corporate Affairs
SAN RAFAEL, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical
Inc. (Nasdaq:BMRN) today announced the appointment of Richard Ranieri as
Senior Vice President, Human Resources and Corporate Affairs. Mr. Ranieri will
start on September 4, 2013.
"We are very pleased to welcome Rich to BioMarin. He brings a wealth of human
resources experience to the company as we continue our rapid growth. He has
the depth and breadth of global experience that BioMarin needs as it scales
its operations to meet its expanding business," said Jean-Jacques Bienaimé,
Chief Executive Officer."As an experienced senior level human resources
executive in the biopharma industry, Rich is extremely well-qualified to fill
this leadership role and will be an instrumental member of the organization."
Mr. Ranieri most recently served as Executive Vice President, Human Resources
at Dendreon Corporation from 2010 to 2013 where he was responsible for all
aspects of human resources and oversaw the expansion of the workforce from 150
to 2,000 employees.Prior to Dendreon, Mr. Ranieri was the Executive Vice
President, Human Resounces & Administration at Sepracor, Inc.where he managed
and directed Human Resources, Corporate Services, Facilities and
Communications.Earlier in his career, Mr. Ranieri served in executive
positions at Neurocrine Biosciences, Inc., Genencor International and
Smithkline Beecham.He received a BA from Villanova University and an MA in
organizational development from Rider University.
BioMarin develops and commercializes innovative biopharmaceuticals for serious
diseases and medical conditions. The company's product portfolio comprises
four approved products and multiple clinical and pre-clinical product
candidates. Approved products include Naglazyme® (galsulfase) for
mucopolysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis
I (MPS I), a product which BioMarin developed through a 50/50 joint venture
with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for
phenylketonuria (PKU), developed in partnership with Merck Serono, a division
of Merck KGaA of Darmstadt, Germany; and Firdapse® (amifampridine), which has
been approved by the European Commission for the treatment of Lambert Eaton
Myasthenic Syndrome (LEMS). Product candidates include Vimizim
(N-acetylgalactosamine 6-sulfatase), formally referred to as GALNS, which
successfully completed Phase III clinical development for the treatment of MPS
IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is
currently in Phase III clinical development for the treatment of PKU, BMN-701,
a novel fusion protein of insulin-like growth factor 2 and acid alpha
glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development
for the treatment of Pompe disease, BMN 673, a poly ADP-ribose polymerase
(PARP) inhibitor, which is currently in Phase I/II clinical development for
the treatment of genetically-defined cancers, and BMN-111, a modified
C-natriuretic peptide, which is currently in Phase I clinical development for
the treatment of achondroplasia. For additional information, please visit
www.BMRN.com. Information on BioMarin's website is not incorporated by
reference into this press release.
Vimizim™ is our trademark, and BioMarin^®, Naglazyme^®, Kuvan^®, Firdapse^®
are registered trademarks of BioMarin Pharmaceutical Inc.
Aldurazyme^® is a registered trademark of BioMarin/Genzyme LLC.
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. Logo
Press spacebar to pause and continue. Press esc to stop.